Zhengye Biotechnology Holding (ZYBT) Inventory Average (2024 - 2025)
Zhengye Biotechnology Holding (ZYBT) posted quarterly Inventory Average of $6.5 million for Q4 2025, down 19.78% year-on-year from $8.1 million in Q4 2024, and down 16.58% on a QoQ basis from $7.8 million in Q2 2025.
Zhengye Biotechnology Holding (ZYBT) Inventory Average (2024 - 2025) Analysis & Trends
Zhengye Biotechnology Holding (ZYBT) has reported Inventory Average for 2 consecutive years, with $6.5 million the latest figure, recorded in Q4 2025.
- Quarterly Inventory Average fell 19.78% year-over-year to $6.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.5 million (down 19.78% YoY) and the FY2025 annual result came in at $6.8 million, down 15.53% from the prior year.
- Inventory Average declined to $6.5 million in Q4 2025 per ZYBT's latest filing, from $7.8 million in the prior quarter.
- Over the last five years, Inventory Average for ZYBT reached as high as $8.1 million in Q4 2024 and fell as low as $6.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 1.45 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.18 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 2.51 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 9.02 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 180.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 2.11 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 3.96 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 66.75 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 1.73 Bn |
| 10 | Zhengye Biotechnology Holding | 85.23 Mn | 85.93 Mn | - | 6.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.50 Mn |
| Jun 30, 2025 | 7.79 Mn |
| Dec 31, 2024 | 8.10 Mn |